Scientists have reported on Apr. 9 that a patient with three severe autoimmune diseases has achieved remission for a year following treatment with CAR-T cell therapy. The case, published in the journal Med, describes how the patient, who previously needed daily blood transfusions and had not responded to years of conventional treatments, experienced significant improvement after receiving this advanced cell therapy.
The report highlights the potential of CAR-T therapies to address complex and life-threatening autoimmune conditions that do not respond to standard care. This development could represent an important step forward for patients suffering from multiple or resistant autoimmune disorders.
Fabian Müller of University Hospital Erlangen in Germany said, "The treatment was extremely efficient in getting rid of all three autoimmune conditions at once." He added, "After being sick for more than a decade, the patient is now in treatment-free remission and able to return to an almost normal life. This therapy significantly improved her quality of life."
The 47-year-old woman suffered from autoimmune hemolytic anemia (AIHA), immune thrombocytopenia (ITP), and antiphospholipid antibody syndrome—three illnesses that affected her blood cells in different ways and led to both bleeding risks and clotting dangers. Over more than ten years since diagnosis, she underwent nine types of treatments without lasting results before being referred to Müller's team.
Müller’s group extracted her T cells—a type of white blood cell—and re-engineered them so they would target B cells carrying the CD19 protein. These B cells were believed responsible for driving her illnesses. After infusion back into her body as CAR-T cells, she required only one more transfusion before reporting increased strength within two weeks and normalized hemoglobin levels by week three.
"After more than ten years of illness, the patient's blood counts normalized within just a few weeks. The speed and depth of the response was remarkable," Müller said. He also explained that when her B cells returned months later they were mostly naive cells: "suggesting the treatment reset her immune system." One year after treatment ended she remains free from transfusions or other therapies; some mild laboratory abnormalities persist but may be linked to previous treatments rather than CAR-T itself.
Müller concluded: "We believe that using CAR-T therapy earlier for patients with severe autoimmune disease could help prevent complications from years of ineffective treatments... If we can intervene sooner, we may be able to stop the disease process, avoid organ damage, and give patients their lives back." Funding for this research came from several German research institutions.
